Cite
HARVARD Citation
Bringhen, S. et al. (2018). Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. Critical reviews in oncology/hematology. pp. 27-35. [Online].